Does Compounded Tirzepatide Work? What the Evidence Shows
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded tirzepatide is not the same as brand-name products such as Zepbound or Mounjaro and may differ in formulation, purity, and potency.
You want an honest answer before you spend money: does compounded tirzepatide actually work? The short version is that tirzepatide has strong clinical-trial evidence, but that evidence comes from the FDA-approved brand-name product. Compounded versions have not been evaluated by the FDA, so you cannot assume a compounded product performs like the product that was studied. Here is what the evidence shows, how compounded tirzepatide relates to it, and what affects results.
The short answer
Tirzepatide has been studied in several large clinical trials. In those trials of the FDA-approved brand-name product, participants lost a meaningful amount of weight on average. That evidence is real, and it is the reason tirzepatide is talked about so much.
Here is the important distinction. The trials were run on the manufacturer’s own FDA-approved product. Compounded tirzepatide contains tirzepatide, but it is not the same product. The FDA does not review compounded drugs for safety, effectiveness, or quality[6], so the FDA has not evaluated whether compounded tirzepatide works. We also did not find any large randomized trial of compounded tirzepatide when we searched PubMed on October 16, 2026. A compounded product can differ in formulation, purity, and potency. So the honest framing is this: the FDA-approved product has strong evidence behind it, and that evidence does not transfer automatically to a compounded version. Results vary, and weight loss is not guaranteed.
What the clinical evidence shows for tirzepatide
The main weight-management trial for tirzepatide is SURMOUNT-1, published in the New England Journal of Medicine in 2022. It enrolled 2,539 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (excluding diabetes), who received weekly tirzepatide injections (5mg, 10mg, or 15mg) or placebo for 72 weeks[1]. The FDA-approved label pairs the medication with a reduced-calorie diet and increased physical activity[3].
In that trial of brand-name tirzepatide, participants on the 15mg dose lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo[1]. The trial also looked at how many people crossed different weight-loss thresholds, because an average alone hides how widely results are distributed.
One reason tirzepatide is studied so closely is its mechanism. It is a GIP receptor and GLP-1 receptor agonist[3], meaning it acts on two gut-hormone pathways rather than the GLP-1 pathway alone. In plain terms, both pathways are involved in appetite and how your body handles food, and tirzepatide engages both.
The trials also show what happens when people stop. In SURMOUNT-4, adults who had lost an average of 20.9% over a 36-week lead-in were randomly assigned to keep taking tirzepatide or switch to placebo. Over the next 52 weeks, the placebo group regained an average of 14.0% of body weight, while the group that continued lost a further 5.5%[2]. Stopping often leads to regain, so any change should be planned with a prescriber.
Tirzepatide has risks as well as benefits. In SURMOUNT-1, the most common side effects were gastrointestinal, mostly mild to moderate and mostly during dose increases, and 6.2% of participants on 15mg stopped treatment because of side effects, compared with 2.6% on placebo[1]. On the Zepbound label, the most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux. The label carries a boxed warning about thyroid C-cell tumors, and tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Because tirzepatide slows stomach emptying, the label also advises people taking birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase[3]. Label information describes the brand-name product; compounded tirzepatide has not been evaluated by the FDA.
A few things are worth keeping in mind when you read those numbers. They describe the FDA-approved brand-name product as studied in clinical trials. They are averages and proportions across a large group, not a prediction for any one person. And participants received counseling on diet and physical activity alongside the medication, so the trial results reflect medication plus that support.
For a closer look at what results can look like over time and how widely they vary, see our write-up on tirzepatide before and after.
How compounded tirzepatide relates to this evidence
This is the part that matters most for your decision, so it is worth being precise.
Compounded tirzepatide contains tirzepatide, the molecule studied in the SURMOUNT trials, but it is not FDA-approved and may differ from the studied product in formulation, purity, and potency. The connection is the molecule, not the product. The trials evaluated brand-name tirzepatide, which Eli Lilly and Company sells as Zepbound and Mounjaro[3][4]. They did not study compounded versions.
Compounded medications are prepared by state-licensed compounding pharmacies or FDA-registered outsourcing facilities. They are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they are marketed[6]. FDA has also warned that some unapproved GLP-1 products may contain too little, too much, or no active ingredient, and that some sellers falsely label semaglutide or tirzepatide “for research purposes” or “not for human consumption”[6]. Because of all that, you should not assume a compounded product and the brand-name product are the same. We are not telling you compounded tirzepatide works “the same as” or is “equivalent to” brand-name tirzepatide, because no one can claim that about a medication the FDA has not evaluated.
Compounded products available today can also differ in ways that go beyond quality. A 2026 review of compounding pharmacy websites found compounded tirzepatide and semaglutide products sold with added ingredients (such as vitamin B12) or as under-the-tongue and dissolving tablets, and concluded that evidence for the safety and efficacy of these products is lacking[7].
The FDA also tracks problems reported after use. As of May 31, 2026, the FDA had received more than 730 adverse event reports associated with compounded tirzepatide. FDA notes that it is not always possible to tell whether an event was caused by the drug or by other factors[6].
Regulatory status matters too. FDA first determined that the tirzepatide injection shortage was resolved on October 2, 2024, and after re-evaluating, issued a new decision on December 19, 2024, that it was resolved. After a federal court denied a preliminary injunction on March 5, 2025, FDA stated that the period in which it did not intend to act against state-licensed 503A pharmacies over shortage-dependent conditions had ended; for 503B outsourcing facilities, that period ran until March 19, 2025[5]. FDA’s compounding policy page was last updated April 1, 2026; check it for the current statement[5]. Availability depends on FDA policy and state and federal pharmacy law, and it may change.
What we can say honestly is that brand-name tirzepatide has been studied carefully, that compounded tirzepatide contains the same molecule without the same FDA review, and that at most telehealth programs a licensed provider decides whether a prescription is appropriate for your health history. If you want to see how this compares with the other commonly compounded GLP-1, our page on whether compounded semaglutide works covers the same ground for that molecule.
One practical note specific to tirzepatide: as of October 2026, FDA-approved tirzepatide comes only as a once-weekly injection[3][4]. There is no FDA-approved oral tirzepatide. Any oral tirzepatide is compounded, is not FDA-approved, and was not the product studied in the trials above.
What affects whether it works for you
Even setting aside the brand-versus-compounded distinction, “does it work” is never only about the medication. Tirzepatide reduces appetite and slows digestion[3], which makes it easier to eat less, but it does not override everything else. Several factors shape how much it helps any individual.
Correct dose titration. On the FDA-approved label, tirzepatide starts at 2.5mg once weekly for 4 weeks and increases in 2.5mg steps at least 4 weeks apart[3]. The starting dose is meant for getting used to the medication, not for weight loss. Reaching and tolerating an appropriate dose, on a schedule your prescriber sets, is one of the biggest drivers of results. Dosing for a compounded product is set by the prescriber and has not been reviewed by the FDA.
Consistent weekly injection. Tirzepatide is taken once a week. Missing doses or stretching out the schedule can keep you at lower levels longer and blunt the effect. Steady, as-directed use matters.
Nutrition and protein. The medication makes it easier to eat less, but food choices still count. Adequate protein and a reasonable eating pattern help support body composition while you lose weight. Our guide on a high-protein approach while on a GLP-1 covers this in practical detail.
Activity, especially strength work. Combining the medication with regular movement, particularly resistance training, supports more favorable changes in body composition.
Sleep and stress. Chronic poor sleep and ongoing high stress can work against weight loss. These are not character flaws, they are physiology, and they are worth raising with your prescriber, or with a coach or dietitian if your program offers one.
Individual biology. People differ in how they respond to GLP-1 medications, partly due to genetics and metabolic factors. Some respond readily, others more modestly. This is real, it is not about effort, and a licensed provider can help you set expectations specific to you.
What a realistic timeline looks like
Weight loss on tirzepatide is rarely fast or linear, and knowing that up front helps you stick with it through the slow stretch.
In the first several weeks, while the dose is low, most people feel only a modest change in appetite and may see little movement on the scale. The early weeks are often more about tolerating the medication than about results. As the dose increases over the following weeks, many people notice reduced appetite and quieter food cravings. Weight loss generally builds gradually over months as the dose reaches an effective level and supporting habits take hold.
The practical takeaway is patience. If the first month feels slow, that is consistent with how the medication is designed to be used, not a sign that it is failing. For a fuller, month-by-month picture, see how long a GLP-1 takes to work.
When it may not work as expected
Sometimes results fall short of what someone hoped for. A few common reasons, most of which are addressable:
- Under-titration. Staying at a low dose for too long is one of the most common reasons results stall. The prescriber sets the dose schedule, so raise it with them.
- Missed or inconsistent doses. Gaps in the weekly injection can keep the medication from reaching steady levels.
- Limited lifestyle support. Without adequate protein, nutrition, movement, and sleep, the medication has less to build on.
- Expectations set too high. Trial averages are not promises. Comparing your week-four progress to someone else’s six-month results, or to a headline number, can make normal progress feel like failure.
- Individual biology. Some people respond more modestly, and that is not something you did wrong.
There is also the point we keep returning to: because compounded tirzepatide is not FDA-evaluated, differences in formulation or potency could play a role in how a given product performs. A licensed provider can review your situation, check that the dose and approach make sense, and help you decide on next steps if results are not where you expected. Results vary, and weight loss is not guaranteed.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedTransformation Health does not accept payment from providers. How we make money.
Citations
[1] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
[2] Aronne LJ, Sattar N, Horn DB, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/
[3] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[4] U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf
[5] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16.)
[6] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026; adverse event counts as of May 31, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16.)
[7] Belcourt J, Sapowadia A, White CM. “Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.” Ann Pharmacother. 2026;60(9):902-906. https://pubmed.ncbi.nlm.nih.gov/41689811/
Important disclosures
The clinical-trial figures in this article describe tirzepatide as studied in trials of the FDA-approved brand-name product. They are not a description of compounded tirzepatide results, and they are not a prediction of what you or any individual will achieve. Results vary, and weight loss is not guaranteed.
Compounded tirzepatide is not FDA-approved, and the FDA does not review compounded medications for safety, effectiveness, or quality. It may differ from brand-name tirzepatide in formulation, purity, and potency, so identical results cannot be assumed. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate.
If you are weighing whether to start, the most useful step is a conversation with a licensed provider who can review your health history and help you understand what a realistic outcome looks like for your situation.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded tirzepatide is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded tirzepatide is not the same as brand-name products such as Zepbound or Mounjaro and may differ in formulation, purity, and potency. Clinical trial data on this page (SURMOUNT-1, SURMOUNT-4, and the Zepbound label) applies to the brand-name product studied. Results vary. Trial results describe study participants and are not a prediction for any individual. Availability of compounded tirzepatide depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by Eli Lilly and Company. Transformation Health does not accept payment from providers. How we make money.